<p>Supplementary Table 1: Baseline characteristics of unmatched patients by switch group</p><p>Total excluded population post-matching</p><p>Variable (at baseline) NTZ IFN/GA n 2508 278 Female, % 69.5 85.4 p-value <0.001</p><p>Age, median 37 35 (IQR) (29,44) (29, 43) p-value 0.497</p><p>Disease duration, median (IQR) 6.9 (3.5,11.8) 5.1 (2.5,9.5) p-value 0.003</p><p>Proportion disease duration on DMT, median (IQR) 0.6 (0.4,0.8) 0.2 (0.1,0.3) p-value <0.001</p><p>Number of DMT starts mean (SD) 1.6 (0.8) 1.2 (0.6) p-value <0.001</p><p>Number of DMT starts / disease duration, mean (SD) 0.3 (0.4) 0.4 (0.5) p-value 0.438</p><p>Baseline EDSS, median (IQR) 3.5 (2, 4.5) 2 (1, 2.5) p-value <0.001</p><p>Total relapse onsets last 12 months, mean (SD) 2.1 (1.1) 1.5 (0.7) p-value <0.001</p><p>Total steroid-treated relapses last 12 months, mean (SD) 1.9 (1.1) 0.3 (0.6) p-value <0.001</p><p>Total relapse onsets last 24 months, mean (SD) 3.1 (1.6) 2.2 (1.3) p-value <0.001</p><p>Total steroid-treated relapses last 24 months, mean (SD) 2.7 (1.5) 0.3 (0.6) p-value <0.001</p>